Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01153945
Recruitment Status : Withdrawn (The sponsor stopped the study.)
First Posted : June 30, 2010
Last Update Posted : April 7, 2015
Information provided by (Responsible Party):
Meir Medical Center

Brief Summary:

Much experimental data has suggested that thyroid hormones (T3 and T4) may modulate neoplastic cells and that T3/T4 deprivation may remove this stimulus. It is now well established that T3/T4 affects cell division/angiogenesis through binding to integrin avb3, commonly over-expressed on many cancer cells. In the experimental settings, mimicking hypothyroidism in the cells is a difficult task. Currently, the use of charcoal stripped serum is used. Using this method, the serum is stripped not only from T3 and T4, as intended, but also from central and important cytokines and growth factor. This leads to a reduced rate of cancer cell proliferation and thus, does not reflect the natural environment in which cancer cells residue under hypothyroid conditions.

The investigators aim to characterize and establish the effects of serum from hypothyroid patients on the proliferation/viability of a variety of cancer cell models.

Condition or disease
Thyroid Cancer

Study Type : Observational
Actual Enrollment : 0 participants
Official Title: Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum
Study Start Date : February 2011
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Non hypothyroid
Healthy subjects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Thyroid cancer patients before/after radioactive iodine total body scan or treatment admitted to the Endocrinology Institute, Meir Medical Center

Inclusion Criteria:

  • Hypothyroid state

Exclusion Criteria:

  • Non hypothyroid state

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01153945

Meir Medical Center
Kfar-Saba, Israel
Sponsors and Collaborators
Meir Medical Center
Principal Investigator: Dan Nabriski, MD Meir Medical Center

Responsible Party: Meir Medical Center Identifier: NCT01153945     History of Changes
Other Study ID Numbers: 097-2010
First Posted: June 30, 2010    Key Record Dates
Last Update Posted: April 7, 2015
Last Verified: August 2011

Keywords provided by Meir Medical Center:
Hypothyroid and non hypothyroid

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs